Gastrointestinal Cancer News

Celyad Oncology placed a voluntary pause on a clinical trial of CYAD-101 after two patients treated with the investigational chimeric antigen receptor T-cell therapy died.

Rare Disease Day is Feb. 28.

Sotorasib demonstrated clinically meaningful anticancer activity in patients with heavily pretreated KRAS G12C-mutated advanced pancreatic cancer, according to study results presented during the ASCO Plenary Series.

Stomach cancer — also known as gastric cancer — is uncommon in the United States, making up only 1.4% of all new cancer cases in 2021, and the number of people diagnosed with it each year is declining.

Consumption of unprocessed red or processed meat did not impact risk for colon cancer recurrence or mortality, according to a prospective cohort study of patients with stage III colon cancer published in JAMA Network Open.

Screening for hepatocellular carcinoma is critical in high-risk patients, according to a presentation at GUILD conference 2022.

Only 7.5% of oncology trials conducted between 2008 and 2020 investigated surgical interventions, according to study results published in JAMA Network Open.

The FDA approved FoundationOne CDx as a companion diagnostic to identify patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab, according to a press release from the test’s manufacturer.

The FDA granted orphan drug designation to CYNK-101, an investigational natural killer cell-based therapy for treatment of advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.

Treating high-grade squamous intraepithelial lesions — primarily with office-based electrocautery — led to an almost 60% reduction in anal cancer incidence among people with HIV, according to the results of a randomized controlled trial.